In accordance with the metabolic and morphological rescue described in treated muscles, we assessed that other proteins acting synergically with mTOR such as GSK-3β and PGC-1α were differentially expressed, enhancing regulation of protein turnover and muscle oxidative capacity and reducing sarcopenia and muscle fiber growth as previously described [26,49,50,51]. The gene discussed is PPARGC1A; the disease is sarcopenia.